arrow
S

Silvia Bozzarelli

humanitas cancer center
H指数:17
被引数:1,014

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

From trial efficacy to real-world effectiveness: evaluating the generalizability of cisplatin–gemcitabine–durvalumab in advanced biliary tract cancers

从临床试验疗效到真实世界有效性:评估顺铂-吉西他滨-度伐利尤单抗在晚期胆道癌中的普适性

2026-11-040
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma

中心级方案依从性对胰腺导管腺癌新辅助治疗结局的影响

2026-09-010
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
FOLFOX Versus FOLFIRI as Second-Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study
2025-12-300
PRE
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial

术前mFOLFIRINOX与PAXG对比治疗I~III期可切除及临界可切除胰腺导管腺癌(PACT-21 CASSANDRA):一项随机、开放标签、2×2析因设计III期试验的首个随机化分析结果

2025-11-200
PRE
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma

一项关于术前化疗联合mFOLFIRINOX或PAXG方案治疗I-III期胰腺导管腺癌的随机III期试验结果

2025-10-310
PRE
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi- Institutional Based survey of Adjuvant and fi rst-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI)
2025-01-010
OAAI
Depicting the cellular complexity of pancreatic adenocarcinoma by Imaging Mass Cytometry: focus on cancer-associated fibroblasts

通过成像质量细胞仪描绘胰腺癌的细胞复杂性: 关注癌症相关的成纤维细胞

2024-11-070
OAAI
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden
2024-11-040
OAAI
Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LUMACA study

孤立性肺转移瘤在胰腺腺癌患者中的多中心意大利队列研究:LUMACA研究

2024-09-010
PRE
Multivariable analysis of streptozotocin plus 5-fluorouracil and everolimus sequences in advanced pancreatic neuroendocrine tumor patients: The SEQTOR trial (GETNE-1206)

多变量分析链脲佐菌素联合5-氟尿嘧啶和依维莫司的顺序疗法在晚期胰腺神经内分泌肿瘤患者中的应用:SEQTOR试验(GETNE-1206)

2024-09-010
PRE
Non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) guideline application in real-world: MultiInstitutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI)
2023-10-010
OA
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial
2023-06-012
PRE